Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s December quarterly update.
Analyst Seth Lizee commented:
“The company is looking to shake up big markets in dermatology and antimicrobials with its four clinical programs. The prize, should individual programs ultimately be clinically successful, is huge.”
Botanix Executive Director, Matt Callahan, recently participated in the ShareCafe Small Cap ‘Hidden Gems’ Webinar.
His presentation provided an overview of our clinical pipeline, including the significant potential for new dermatology products and opportunities for adding new assets to our pipeline. Matt also shared an update on upcoming clinical and operational milestones for 2022.
Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s December quarterly report.
2022 is described as “a big year ahead”.
Botanix is one of only 34 companies selected to participate in the 2022 Edison Open House: Global Healthcare virtual event to be hosted by the Edison Group next week.
Join Botanix’s Executive Director, Matt Callahan, and science journalist, Vivienne Parry, at 7pm AEST on Tuesday 25th January 2022, as they discuss the upcoming developments for our dermatology and antimicrobial programs.
Click here to register, it’s free.
Last week, the Edison Group also published a quickview analyst report on Botanix Pharmaceuticals, an interesting snapshot of what’s to come for the Company in 2022.
At Botanix, we genuinely believe in the therapeutic potential of CBD to treat serious medical conditions … and clearly we’re not alone.
Last month, pharmaceutical company Pfizer announced its entry into the cannabinoid space after sharing news of its planned acquisition of clinical-stage company Arena Pharmaceuticals for a total equity value of around US$6.7 billion.
According to the official press release from Pfizer, Arena holds a ‘diverse and promising’ portfolio, including an innovative CB2 agonist and dermatological disease candidate.
While the world continues to battle COVID-19, experts are concerned that older, sick and vulnerable patients may be at increased risk of AMR. According to an article in The Lancet, 1 in 7 patients hospitalised with COVID-19 have “acquired a dangerous secondary bacterial infection, and 50% of patients who have died had such infections.”
At Botanix, we are exploring the potential of synthetic CBD to develop novel therapies to address AMR, and ultimately reduce the dependence on broad-spectrum antibiotics.
According to WHO Director-General Tedros Adhanom Ghebreyesus, antimicrobial resistance is “one of the greatest health threats humanity faces today”.
The Center for Disease Control and Prevention (CDC) estimates that each year in the U.S., at least 2.8 million people get an antibiotic-resistant infection, and more than 35,000 people die. The reality is, #AMR can affect anyone.
At Botanix, we are working proactively to develop alternatives for broad-spectrum antibiotics in the clinic. Our BTX 1801 pipeline is focused on testing the capabilities of synthetic cannabidiol for fighting antibiotic resistance, and to develop a novel platform product for multiple human and animal health applications.
Spread awareness, stop resistance.
With a successful track record of commercialising therapies in the antimicrobial space, and over 18 years of experience in senior commercial leadership within the pharmaceutical sector, Lynda Berne is well equipped to lead the commercial strategy for Botanix’s antimicrobial asset BTX1801.
“BTX1801 is an extremely interesting therapy, as it is the first and only CBD antimicrobial that has shown potent bactericidal activity against gram-positive pathogens with no development of resistance, as well as effective eradication of Staphylococcus aureus in nasal carriers, while maintaining an excellent safety and tolerability profile.”
Lynda is currently collaborating with the clinical team to build the commercial strategy and determine the optimal pathway to market for BTX1801.
“We are evaluating various patient populations at high risk of S. aureus bloodstream infections. This has led us to identify haemodialysis patients who use central venous catheters for dialysis as a population at very high risk of bloodstream infections.
“There are currently no therapies approved to reduce the risk of bloodstream infections among haemodialysis patients, which creates a significant opportunity for Botanix.”
Lynda is currently working with health economists and key opinion leaders in nephrology and infectious disease to provide input into Botanix’s clinical trials program and health economic outcomes research plan, with a view to sharing study outcomes with investors and potential partners.
“Our priority right now is to raise awareness of the unmet need and economic burden of bloodstream infections in this population, and to position BTX1801 as the solution.”
Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s September quarterly update.
Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the Company’s release of a clinical development update on the atopic dermatitis and rosacea programs.
